...Teva Strategy Overview February 21, 2008 Forward-Looking Statements TODAY S PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS, WHICH EXPRESS THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT. SUCH STATEMENTS INVOLVE A NUMBER OF KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES THAT COULD CAUSE TEVA'S FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS TO DIFFER SIGNIFICANTLY FROM THE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARDLOOKING STATEMENTS. IMPORTANT FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE RISKS RELATING TO: TEVA'S ABILITY TO ACCURATELY PREDICT FUTURE MARKET CONDITIONS, TEVA'S ABILITY TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE ADDITIONAL PHARMACEUTICAL PRODUCTS, THE INTRODUCTION OF COMPETING GENERIC EQUIVALENTS, THE EXTENT TO WHICH TEVA MAY OBTAIN U.S. MARKET EXCLUSIVITY FOR CERTAIN OF ITS NEW GENERIC PRODUCTS AND REGULATORY CHANGES THAT MAY PREVENT TEVA FROM UTILIZING EXCLUSIVITY PERIODS, COMPETITION FROM BRAND-NAME COMPANIES THAT ARE UNDER INCREASED PRESSURE TO COUNTER GENERIC PRODUCTS, OR COMPETITORS THAT SEEK TO DELAY THE INTRODUCTION OF GENERIC PRODUCTS, POTENTIAL LIABILITY FOR SALES OF GENERIC PRODUCTS PRIOR TO A FINAL RESOLUTION OF OUTSTANDING PATENT LITIGATION, INCLUDING THAT RELATING TO THE GENERIC VERSIONS OF ALLEGRA , NEURONTIN , LOTREL , FAMVIR , AND PROTONIX , THE IMPACT OF CONSOLIDATION OF OUR DISTRIBUTORS AND CUSTOMERS, THE EFFECTS OF COMPETITION ON OUR INNOVATIVE PRODUCTS, ESPECIALLY COPAXONE SALES, THE IMPACT...
Words: 7679 - Pages: 31
...Case Study TEVA Strengthens Security for Software Assets with MKS Integrity “One of the main measures for success in the implementation of the MKS Integrity Suite was the reduction in the amount of paper and forms that get manually pushed from person to person. By simply automating service request forms and routing them via electronic workflows we have become much more effective, and dramatically reduced our time spent managing projects.” Tom Loane, Chief Information Officer , TEVA Pharmaceuticals Company Overview TEVA USA is a wholly-owned subsidiary of TEVA Pharmaceutical Industries Ltd., Israel’s largest pharmaceutical manufacturer operating globally in 30 countries on 5 continents. TEVA is among the top 20 pharmaceutical companies and the largest generic pharmaceutical companies in the world. The company has approximately 14,000 employees worldwide with production facilities in Israel, North America, Europe and Mexico. TEVA USA has an aggressive Research & Development effort and one of the best overall ANDA approval records in the industry. The company’s mission is to play a leading role in the transformation of the U.S. healthcare system through its preeminence in the development, manufacturing and marketing of pharmaceuticals. The Challenge As a pharmaceutical company operating in the U.S., TEVA must comply with Food and Drug Administration (FDA) regulations. The FDA requires stringent application development and change control practices surrounding software...
Words: 1059 - Pages: 5
...Teva Pharmaceuticals LTD Clinton Stucker American Military University Abstract In this paper we will discuss the competitive advantage of Teva Pharmaceuticals as well as Teva’s resources to continue to grow and remain dominant within the pharmaceutical industry. As industries evolve it is important for companies to evaluate their strengths and weaknesses in order to maximize their potential to succeed. In this paper we will evaluate Teva’s greatest strengths and resources that will enable the company to continue to grow and compete within the generic drug industry. This paper will be a guideline for how Teva should move it company forward in the future. Introduction Teva pharmaceuticals is known for its operational efficiency within the generic pharmaceutics industry. Information gathered from TevaPharm.com provides a clear picture of how the company is so successful within the pharmaceutical industry; Teva pharmaceuticals operates globally within sixty countries and consists of fifty four pharmaceutical production plants. The Teva company is a global industry that maintains a completive advantage as “During 2012, Teva's plants manufactured approximately 73 billion tablets and capsules and over 720 million sterile units (Tevapharm.com)”. Teva’s Competitive Advantage The Teva pharmaceutical company enjoys a serious competitive advantage within the generic pharmaceutical industry. Their biggest advantages include their operational expertise as well as their immense...
Words: 885 - Pages: 4
...Teva Pharmaceutical Industries, Ltd 1) External Environment: The Pharmaceutical Industry is dependent on political and legal conditions of general environment. In pharmaceutical industry we have two kind of medications which are generic or innovative. Innovative pharmaceutical industry success depends on the patent protection in the industry. For example, in United States innovative industry can have 10 to 12 years of patent protection life from the time that product is for sale in the market. Success of the generic pharmaceuticals which are bioequivalent to innovative pharmaceutical is also related to the political and legal environment of their market. If we look at pharmaceutical industry globally we can see that regulations toward generic pharmaceutical are different in different countries. For example, in United States they have the Hatch-Waxman ACT 1984including Abbreviated New Drug Application which reduce the drugs approval period and give the chance to Generic companies to have a 180 day exclusivity period if the generic company can submit an abbreviated new drug application before other generic competitors. In Europe regulations are different in each country for example, United Kingdom and the Netherlands are very similar to USA, and countries such as Germany and France are more physician-driven or branded generics market and the cost of sale for generic products are higher in these countries. Market for generic drugs in the rest of...
Words: 1493 - Pages: 6
...Today, according to TOMS SHOES, is ONE DAY WITHOUT SHOES day. I love the idea. I am barefoot today. But more interesting to the business world, and especially those trying to understand how social media marketing can work for them, and how to market a concept or idea over a product, TOMS SHOES is a fascinating case study. TOMS is a for-profit company with a social cause. TOMS has a model of buy one, give one. For every pair of shoes bought, TOMS donates a pair to someone in the developing world who has no shoes. The company was founded in 2006, and has taken off. SO much so that TOMS has the marketing power to put together a day where more than one million people will go all day without shoes on. They have done a lot of things right, including creating a beautiful YOU TUBE video explaining the ONE DAY WITHOUT SHOES concept. The founder of TOMS explains in a USA TODAY article why he decided to found a for-profit company instead of a charitable organization: “When I first decided that I wanted to do something about this problem, I had a few options. I could have written a check to a charity or foundation for a one-time donation. But it didn’t feel right. By being a for-profit, we’re more sustainable,” he explains. In the world of entrepreneurship, I admire and respect Blake Mycoskie. He has started a company doing something that he loves, is passionate about, and can also do some social good. He has been super smart about how to get the message out about what and how he is doing...
Words: 359 - Pages: 2
...Dossier Management des Risques Criminels : TEVA Pharmaceutical Industries Problématique : Comment prévoir la menace criminelle de TEVA Pharmaceutical Industries ? Quels sont les risques criminels que TEVA doit prendre en compte dans son activité? (http://www.tevapharm.com/) I. Description de TEVA Pharmaceutical Industries TEVA Pharmaceutical Industries est une entreprise pharmaceutique spécialisée dans le médicament générique. Avec un chiffre d’affaire de plus de 16 milliards de dollars en 2010, TEVA est l’une des 25 plus grosses industries pharmaceutiques mondiales. Le siège social de l’entreprise se trouve à Petah Tikva en Israël et le groupe compte de nombreuses filiales à travers le monde. A/ Attentat. Le siège social de TEVA se trouve en Israël à Petah Tikva. Septième ville d’Israël et situé au Nord est de Tel Aviv...
Words: 1218 - Pages: 5
...9-707-441 REV: MARCH 30, 2010 TARUN KHANNA KRISHNA PALEPU CLAUDINE MADRAS Teva Pharmaceutical Industries, Ltd In Israel we have a 1970s song based on a poem from 1953 by Amir Gilboa about Theodor Herzl.1 It has a line in it about Herzl: “Suddenly a man rises in the morning, feels he is a people, and starts walking.” That is exactly what Hurvitz did. Suddenly he woke up in the morning, feels he is a giant world class company, and starts walking. No one, aside from Herzl, has accomplished anything as remotely as impressive in this country as Hurvitz. It was impossible, a million to one odds at best, and he still did it. He woke up one morning and started walking. — Ori Hershkovitz, equity analyst at Tel Aviv-based Leader & Company The markets had not been kind to Teva Pharmaceutical during the first half of 2006. The stock had plunged nearly 30% from January 1 to June 30, erasing billions of dollars from the company’s market capitalization. Even good news, such as reports in July of Teva’s wildly successful introduction of generic Zocor—the largest blockbuster drug ever to go off-patent—had failed to boost the stock significantly. Since nearly every retirement fund and mutual fund in Israel invested in Teva, this drop had been felt throughout the population, in effect amounting to every Israeli family losing NIS 3000, or $675.1 Teva was more than the world’s leading producer of generic pharmaceuticals (see Exhibit 1 for financials). It represented the gold standard of business...
Words: 12524 - Pages: 51
...Running Head: Decisions in Paradise Part II Decisions in Paradise Part II NAME MGT 350 January 23, 2012 Introduction Within the context of Decisions in Paradise I, I discussed some of the different obstacles that TEVA, USA is encountering while trying to enter the country of Kava, a South Pacific Island. I also shared different approaches that my company TEVA, USA can take to address the many challenges that the island presents. Any solution that I, or my partners, propose will have an effect on Kava and this should be taken into consideration when implementing our techniques. The process of assessing the available solutions will be explored within Decisions in Paradise II. The most difficult problem to overcome is that Kava is a hard island to inhabit because of the unavoidable issues the face with disasters and disease. In addition to the mess that the island is in, the office that TEVA occupies is also in havoc. They lack sufficient employees and the office in unorganized. After identifying the problems at hand, I have determined that the basic solutions would be; hire a new receptionist, clean up the office space, and implementing contingency plans for every natural disaster that may impact the land. This would include a safety plan, a cleaning plan, and a safe place for everyone to go when disasters do strike. Decision-making Technique Several influences have been identified to lead to the issues that are affecting Kava today. The main...
Words: 887 - Pages: 4
...the island to analyze the possibility of the plans of the Teva Pharmaceuticals to increase its presence in the island. Determining Factors Affecting the Decision Implementation The disaster threats relative to the geographic location of Kava pose considerable risks to any business operating in the island. Teva Pharmaceuticals will not be exempted from that. The threats also pose real danger to the health of the people of Kava. The risks from the disaster threats could significantly affect the health of the population particularly if accessibility to affordable health and medical supplies is difficult. The threats from AIDS/HIV alone could be devastating but the threat could be eased with available protective device such as affordable and easy accessible condom sheaths. The situation in Kava could be a great opportunity for the Teva Pharmaceuticals to expand its mission which is “to play a leading role in the transformation of the U.S. healthcare system through its pre-eminence in the development, manufacture and marketing of generic pharmaceuticals (TEVA USA., 2010, para 2)”. The company can expand that mission to the healthcare system of Kava Island highly vulnerable to many threats particularly storm, tsunami, earthquake, flood, fire, petroleum spills, AIDS/HIV, and avian flu (University of Phoenix, 2010). The condition of Kava may not be highly favorable but the island also has some benefits to offer to Teva...
Words: 1991 - Pages: 8
...PRESCRIPTION SAVINGS CARD First NUVIGIL Prescription FREE* Refills as low as $5* FOR PHARMACISTS First Prescription is FREE* On the first fill, your patient will receive up to 30 NUVIGIL tablets at no cost, subject to terms and limitations. FOR PATIENTS Refills as low as $5* On all future NUVIGIL fills, your patient’s out-of-pocket expense will be as low as $5 for each prescription refill with a maximum savings of up to $50 per prescription. INSURED PATIENT BILLING Submit a primary claim to your patient’s insurance, and then submit a secondary coordination of benefits (COB) claim to AlphaScrip. BIN: 610600 PCN: AS Group and ID numbers: located on the card PRIOR AUTHORIZATION If your insured patient’s insurance provider denied the primary claim due to a Prior Authorization (PA) requirement, please initiate the PA process to help your patient save on future NUVIGIL prescriptions If you have questions regarding prior authorization or need forms to assist your patient initiate the prior authorization process, please go to CoverMyMeds.com for assistance PATIENTS WITHOUT INSURANCE COVERAGE FOR NUVIGIL Submit a primary claim to AlphaScrip using Other Coverage Code: 00 or 01 BIN: 610600 PCN: AS Group and ID numbers: located on the card For assistance or questions regarding pharmacy billing, please contact the AlphaScrip Pharmacy Help Desk at 1-877-274-3244. The correct Other Coverage Code is required (see below). Editing the Other Coverage Code may be necessary. 03:...
Words: 935 - Pages: 4
...Case Study 3.1 Teva Acquires Cephalon in a Hostile Takeover in the European Market for Corporate Control 1. While Valeant was more likely to be an aggressive cost cutter, both firms anticipated improving earnings performance through significant cost savings by combining operations and eliminating duplicate overhead. Valeant also believed Cephalon would complement their own offering. Teva was under pressure to diversify its product offering to include a greater percentage of higher margin branded drugs. Like many pharmaceutical companies, they were vulnerable to the loss of patent protection on a key drug and were seeking access to a firm with a substantial number of new drugs under development. 2. Both firms initially approached Cephalon on a friendly basis, interested in avoiding an auction for the target and the potential for customer attrition, loss of key employees, and disruption to suppliers if the acquisition became hostile. However, Valeant decided to pressure the target by going directly to the shareholders with an all-cash hostile tender offer. Simultaneously, the firm initiated a proxy fight in an attempt to change the composition of the Cephalon board in order to have the board rescind the firm’s shareholder rights plan (poison pill), which if triggered would have increased the cost of the takeover. Valeant used a consent solicitation card which would enable Cephalon shareholders to support Valeant’s slate of directors without scheduling a formal shareholders...
Words: 582 - Pages: 3
...Chapter 4 Case Study: Teva Pharmaceuticals Buys Barr Pharmaceuticals to Create a Global Generic Drugs Powerhouse 1. Why do you believe that Teva chose to acquire the outstanding stock of Barr rather than selected assets? Explain your answer. Answer: Much of the value of Barr is intangible in the form of patents, brand names, and in-process research and development. The latter generally represents unpatented ideas and processes which have not been commercialized but may have the potential to become commercially viable products. When a firm acquires the stock of another firm, it is entitled to all assets (tangible or otherwise) and liabilities that are either on or off the balance sheet. Tax losses and credits and other value attributes such as brand names also pass to the owners of the stock. In a purchase of assets, the acquirer only is entitled to those assets that are listed and appended to the agreement of purchase and sale. Consequently, for a business where intangible assets are so important, a stock purchase would seem the most appropriate form of acquisition. 2. Mergers of businesses with operations in many countries must seek approval from a number of regulatory agencies. How might this affect the time between the signing of the agreement and the actual closing? How might the ability to realize synergy following the merger of the two businesses be affected by actions required by the regulatory authorities before granting their approval? Be specific. Answer:...
Words: 820 - Pages: 4
...Decision in Paradise Pt.2 Your name here: MGT/350 July 20th, 2011 Facilitator: Decision in Paradise Pt.2 Introduction Kava was in need of assistant, and it would take Teva Pharmaceuticals to aid this small island, which must pick the decision-making method that describes/explains the problems, collet data, and permits for pors and cons analysis (Chapman, n.d). However, they will need to provide a way for goals to include the top chances of achievement with the means obtainable with costs implicated, plus recognize the required individuals to emerge not only in the decision-making process except to put into pratice the goal(s) when selected. Applying a decision-making technique Today we have several decision-making methods. A tool for the mind, a well-liked career skills online resource, suggests the following decision-making techniques (n.d.). 1. Pareto Analysis - goals are prioritized then resources are applied to high priority items first, helpful when there are many goals being considered. 2. Paired Comparison Analysis - weigh the reletive importance of different courses of actions, helpful when all facts are not known for making the comparison of apples to oranages, and/or priorities are not clear or complete. 3. Grid Analysis - rank, and then compare the factors that must be considered with goals, choosing the goals with the highest rank; most successful when factors needing considerations are known. ...
Words: 1104 - Pages: 5
...All of the following medications are gluten free unless otherwise noted Generic drugs can be produced from many manufacturers and not all manufacturers use the same fillers or excipients. When there is a generic drug listed the manufacturer will be in the parenthesis. This does not imply that these are the only gluten free manufacturers but that these were the only ones checked. ANALGESICS/NONSTEROIDAL Acetaminophen w Codeine (Teva) Advil Aleve Alka Seltzer Gold Alka Seltzer Heartburn Relief Anaprox Anaprox DS Arthrotec Aspirin Enteric Coated 325mg (Leiner,code #44/227, Watson) Aspirin 81mg chewable (Watson) Avinza Baby aspirin (Walgreens, Perrigo) Bancaps HC Bufferin-all products EXCEPT Bufferin regular 325mg tablet which does contain some gluten Butazolidin Carisoprodol (Watson, West-Ward) Cataflam Celebrex Clinoril Cyclobenzaprine (Mylan, Schein, Watson) Daypro Demerol Durabac Ecotrin (all strengths) Endocet Endodan Esgic (all forms) Excedrin Extra Strength Excedrin Migraine Feldene-contains gluten Fioricet / with Codeine Fiorinal Fiorinal caps-generic (West-Ward) Fiorinal tabs-generic (West-Ward) Fiorinal with Codeine Flexeril Flubriprofen (Novapharm) Hydrocodone/APAP all strengths (Mallinckrodt, Watson) Ibuprofen (Amneal, Pharm. Formulations) Indocin Indomethacin (Novapharm) Ketoprofen XR (Andrx) Lodine (tabs/caps/XL) Lorcet 10/650 Lorcet Plus Lortab (all forms) Motrin Childrens DF Conc. Drops Mobic Morphine IR tabs (Roxane) Morphine Sulfate Ext Release Tab (Endo) Motrin...
Words: 2427 - Pages: 10
...The background of the company with a lifecycle analysis Amgen is a worldwide biotechnology company that develops and distributes medicines that treat millions of seriously ill patients. They were early pioneers starting in 1980, and have grown to be the world’s largest independent biotech headquartered out of Thousand Oaks, California. They currently have a dozen successful FDA approved and profitable drugs (1). Amgen went public in 1984 and currently trade on the NASDAQ under the symbol AMGN. Amgen is officially listed under the Healthcare sector and further classified under the Biotechnology industry (2). They have experienced unprecedented organic growth but also acquired several other public and private companies over the years that had a product with potential, but not the resources to complete the brutal FDA requirements, submission, and approval process successfully. Operating risks are low with Amgen; new drugs are studied under clinical trials for years before approaching the FDA for approval. Once FDA approval is secured, Amgen enjoys long contracts where the drug cannot be copied and sold under a generic brand for a decade or more. Matter of fact, they have won several infringement lawsuits protecting their technology over the years. As stated earlier, they have several approved medicines that are already in the market where they have absolute market penetration. However, over the years contracts expire, and new drugs must be developed. These new sources of...
Words: 1619 - Pages: 7
